Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2018
At a glance
- Drugs Huperzine A (Primary)
- Indications Seizures
- Focus Proof of concept; Therapeutic Use
- Acronyms FIAS
- Sponsors Biscayne Neurotherapeutics; Supernus Pharmaceuticals
- 04 Oct 2018 According to a Supernus Pharmaceuticals company website, the Biscayne Neurotherapeutics is acquired and merged with Supernus Pharmaceuticals.
- 28 Mar 2018 According to Biscayne Neurotherapeutics media release, results are expected later in 2018.
- 21 Mar 2018 Status changed from planning to recruiting.